Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its position in Baxter International Inc (NYSE:BAX) by 3.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,144 shares of the medical instruments supplier’s stock after selling 4,900 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Baxter International were worth $12,051,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its position in Baxter International by 1.5% during the fourth 1,205,779 shares of the medical instruments supplier’s stock worth $79,362,000 after buying an additional 17,633 shares in the last quarter. Geode Capital Management LLC grew its position in Baxter International by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 6,444,204 shares of the medical instruments supplier’s stock worth $423,409,000 after buying an additional 297,006 shares in the last quarter. Mutual Advisors LLC grew its position in Baxter International by 16.6% during the fourth quarter. Mutual Advisors LLC now owns 4,219 shares of the medical instruments supplier’s stock worth $278,000 after buying an additional 600 shares in the last quarter. Cetera Advisors LLC grew its position in Baxter International by 21.9% during the fourth quarter. Cetera Advisors LLC now owns 4,560 shares of the medical instruments supplier’s stock worth $303,000 after buying an additional 820 Phocas Financial Corp. acquired a new stake in Baxter International during the fourth quarter worth approximately $66,000. Hedge funds and other institutional investors own 83.97% of the company’s stock.
Get Baxter International alerts: In other news, insider Third Point Llc sold 5,000,000 shares of Baxter International stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $76.37, for a total value of $381,850,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, Director Thomas T. Stallkamp sold 1,000 shares of Baxter International stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $76.20, for a total value of $76,200.00. The disclosure for this sale can be found here . Over the last ninety days, insiders have sold 5,002,913 shares of company stock valued at $382,077,150. 0.70% of the stock is owned by corporate insiders.
NYSE:BAX traded down $0.26 during trading hours on Friday, hitting $84.90. 63,078 shares of the company were exchanged, compared to its average volume of 2,084,234. The company has a market cap of $42.82 billion, a PE ratio of 27.83, a price-to-earnings-growth ratio of 1.98 and a beta of 0.99. The company has a quick ratio of 1.30, a current ratio of 1.83 and a debt-to-equity ratio of 0.50. Baxter International Inc has a one year low of $61.05 and a one year high of $86.12. The business’s fifty day moving average is $81.11.
Baxter International (NYSE:BAX) last announced its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 the Thomson Reuters’ consensus estimate of $0.81 by $0.08. The business had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.80 billion. Baxter International had a return on equity of 20.04% and a net margin of 14.27%. Baxter International’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period last year, the company earned $0.77 EPS. On average, research analysts anticipate that Baxter International Inc will post 3.32 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 1st. Investors of record on Friday, August 30th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend is Thursday, August 29th. Baxter International’s dividend payout ratio is currently 28.85%.
A number of equities research analysts have weighed in on the company. Raymond James raised their target price on Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a report on Friday. JPMorgan Chase & Co. raised their target price on Vermilion Energy from C$42.00 to C$43.00 in a report on Monday, May 13th. Cowen set a $75.00 target price on Baxter International and gave the company a “hold” rating in a report on Monday, April 22nd. Barclays raised their target price on Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a report on Monday, April 15th. Finally, KeyCorp assumed coverage on Baxter International in a report on Tuesday, June 25th. They issued a “sector weight” rating on the stock. Four investment hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $83.40.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Featured Story: Forex
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Baxter International
